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Blockade of the epidermal growth factor receptor
decreases intimal hyperplasia in balloon-injured rat
carotid artery
Allen K. Chan, MD, Andreas Kalmes, PhD, Suzanne Hawkins, BS, Gu¨nter Daum, PhD, and
Alexander W. Clowes, MD, Seattle, Wash
Hypothesis: Arterial intimal hyperplasia is induced by injury and is frequently the cause of luminal narrowing after vascular
reconstruction. Smooth muscle cells (SMC) respond to injury by proliferating and migrating into the intima. This process
is regulated by thrombin, endothelin, and angiotensin II, all ligands of G protein-coupled receptors. Signal transduction
from these receptors in cultured cells depends in part on transactivation of epidermal growth factor receptor (EGFR). We
hypothesize that EGFR has a substantial role in activation of SMC in vivo and development of intimal hyperplasia.
Methods: Intimal hyperplasia was induced in rat carotid arteries by passage of a balloon catheter. Animals were given a
monoclonal blocking antibody to rat EGFR, matched mouse immunoglobulin G (IgG) control antibody, or saline
solution.
Results: Blocking EGFR antibody inhibited medial SMC proliferation, as determined by 5-bromo-2-deoxyuridine
labeling at 2 days (IgG control, 8.0% 2.0%; anti-EGFR, 3.2% 0.8%) and intimal hyperplasia at 14 days (intimal area:
IgG control, 0.07  0.01 mm2; anti-EGFR, 0.04  0.01 mm2).
Conclusion: Activation of EGFR is important for early induction of SMC proliferation and subsequent intimal
thickening. (J Vasc Surg 2003;37:644-9.)
All forms of arterial reconstruction (eg, balloon or stent
angioplasty, endarterectomy, bypass grafting) injure the
diseased vessel and induce a response that in turn reduces
the size of the lumen either by pathologic remodeling or by
intimal thickening and increase in wall area.1,2 Develop-
ment of intimal hyperplasia and luminal narrowing dimin-
ishes the long-term success of all vascular interventions. For
example, the restenosis rate after percutaneous translumi-
nal coronary angioplasty is 30% to 50%.3 No single agent
has been proved to reliably reduce intimal hyperplasia in
human beings. However, heparin suppresses proliferation
of smooth muscle cells (SMC) in injured arteries of rats,
leading to decreased intimal hyperplasia,4 possibly by inter-
fering with basic fibroblast growth factor signaling. Block-
ade of basic fibroblast growth factor inhibits early SMC
proliferation. Platelet-derived growth factor antagonists
and receptor blocking antibody both are effective in inhib-
iting SMC activation after arterial injury in rodents and
monkeys.5,6 In addition, pharmacologic blockade experi-
ments have established a role for several G protein-coupled
receptor agonists, including thrombin, endothelin, and
angiotensin II.
Thrombin stimulates SMC by cleaving its G protein-
coupled receptor, thereby generating a new N-terminal,
which functions as a ligand.7,8 The thrombin receptor
PAR-1 generates downstream signals through various
pathways.9 Of particular note is the novel observation made
by several laboratories, including our own, that thrombin
signaling depends in part on transactivation of the epider-
mal growth factor receptor (EGFR) by means of an auto-
crine mechanism.10,11 The activated thrombin receptor
induces the release of heparin-binding epidermal growth
factor-like growth factor from the cell membrane, which in
turn binds to EGFR in the context of membrane-associated
heparan sulfate proteoglycan.12 Recent studies with cul-
tured SMC showed that transactivation of EGFR is impor-
tant in activation of SMC not only by thrombin10 but also
by angiotensin II13 and endothelin.14
From these observations we hypothesize that EGFR
blockade decreases intimal hyperplasia in vivo. We tested
this hypothesis using the balloon-injured rat common ca-
rotid artery, a model that has been widely used to study
intimal hyperplasia. Introduction of the balloon strips the
artery of its endothelium and damages the underlying
media. This injury induces proliferation of medial SMC,
migration of SMC into the intima, and subsequent intimal
thickening produced by SMC accumulation and matrix
synthesis.1,2
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Application of a blocking EGFR antibody before bal-
loon injury of the rat carotid artery attenuates intimal
hyperplasia.
METHODS
Carotid artery injury model and morphology. Bal-
loon injury of the left common carotid artery of 4-month-
old male Sprague-Dawley rats (Tyler Laboratories Inc,
Bellevue, Wash) was performed as described.15 Animals
were housed and cared for according to an animal use
protocol approved by the University of Washington. At
various times after injury, animals were given 50 mg 5-bro-
mo-2-deoxyuridine (BrdU, Boehringer, Mannheim, Ger-
many) subcutaneously at 24 hours, and 60 mg/kg Evans
blue intravenously at 30 minutes before the carotid arteries
were perfusion-fixed.15 Re-endothelialization (white or
blue boundary) of the common carotid artery was mea-
sured from the carotid bifurcation.15 BrdU was detected
with mouse anti-BrdU, biotinylated anti-mouse immuno-
globulin G (IgG; Vector Laboratories Inc, Burlingame,
Calif), with a Vectastain ABC Kit (Vector). The cross-
sectional image of the stained slides was then digitally
scanned into the software program SPOT and displayed on
a computer screen, and intimal and medial areas and nu-
clear numbers were determined.
Antibody administration. The EGFR monoclonal
blocking antibody (151-IgG, Developmental Studies Hy-
bridoma Bank, University of Iowa, Ames)16 and control
monoclonal antibody (mAb 1766)17 were provided by
Genentech Inc (South San Francisco, Calif). Animals were
given intraperitoneal injections of either antibody (13.5
mg/kg) or saline solution 12 hours before carotid artery
balloon injury and every 3 days thereafter. Serum levels of
the antibodies were measured with an enzyme-linked im-
munosorbent assay (Mouse IgG ELISA Quantitation Kit,
Bethyl Laboratories, Inc, Montgomery, Tex) at balloon
injury and on days 7 and 12 after injury.
Statistical analysis. Data (mean  SEM) were com-
pared with the nonparametric Mann-Whitney test. Differ-
ences were considered significant at P  .05.
RESULTS
Pharmacokinetics of EGFR blocking antibody in
the rat. Epidermal growth factor receptor blocking anti-
body (13.5 mg/kg) was administered by intraperitoneal
injection 12 hours before balloon injury and 3 days and 7
days after injury. Serum EGFR concentrations (mean 
SEM, n  6) were determined with an ELISA at various
times. At balloon injury, EGFR concentration was 893.3
284.9 g/mL; immediately before the third injection on
Fig 1. Cross section of rat carotid artery. A, Uninjured carotid artery. B to D, Left common carotid arteries of rats
were injured by passage of a balloon catheter and were evaluated in cross section at 14 days. Animals were given
intraperitoneal injections of either saline solution (B), control antibody (C), or epidermal growth factor receptor
blocking antibody (D).
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day 7 it was 728.7  239.2 g/mL; and on day 12 was
654.6 201.3 g/mL). Recently we reported the efficacy
of the antibody with respect to blocking EGFR signaling in
rat SMC10: at a concentration of 100 g/mL the antibody
completely inhibited EGFR phosphorylation and subse-
quent extracellular signal-regulated kinase activation in re-
sponse to EGF.
Intimal hyperplasia at 14 days after carotid balloon
injury is inhibited by anti-EGFR mAb. Sprague-Dawley
rats received intraperitoneal injections of saline solution,
control antibody, or EGFR blocking antibody before bal-
loon injury and every 3 days thereafter. Two weeks after
injury the animals were killed and the perfusion-fixed ca-
rotid arteries were isolated. Two sections per carotid artery
were analyzed. Representative sections of carotid arteries of
uninjured animals and animals that received either saline
solution, control antibody, or EGFR blocking antibody are
shown in Figure 1. The average intimal area from animals
given EGFR blocking antibody was 50% smaller (0.039 
0.006 mm2) than that from animals given control antibody
(0.073  0.009 mm2) or saline solution ( 0.068  0.01
mm2) (Fig 2, A). Consistent with this finding, luminal area
is increased in the presence of EGFR blocking antibody
(0.26  0.01 mm2) compared with control antibody
(0.21  0.02 mm2) or saline solution (0.22  0.02 mm2)
(Fig 2, B). Re-endothelialization of the common carotid
artery was measured proximally from the point of carotid
bifurcation and was increased in the anti-EGFR group
(2.90  0.29 mm) compared with the saline solution
control group (2.05  0.12 mm) (Fig 2, C). Although
statistical significance was lost when compared with the
group that received control antibody (2.25  0.28 mm),
the tendency was the same. There was no significant differ-
ence in medial area or external elastic lamina area between
the three groups (Table). Last we determined the intimal
cell density (cells per 0.5 mm2), and found no difference
between the anti-EGFR group and the control anti-IgG
group (Table).
Fig 2. Quantitation of healing at 14 days after injury. Rats with balloon-injured carotid arteries were given
intraperitoneal injections of either saline solution, control antibody, or EGFR blocking antibody. Intimal (A) and
luminal (B) areas were measured in cross section. Saline solution group, n  12; control antibody group, n  11;
anti-EGFR group, n 12. C, Extent of re-endothelialization of the distal half of injured common carotid arteries was
measured in millimeters of ingrowth from bifurcation. Saline solution group, n  5; control antibody group, n  6;
anti-EGFR group, n  5. Data are presented as mean  SEM.
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Injection of anti-EGFR mAb decreased SMC prolifer-
ation in the media of balloon-injured carotid arteries. To
investigate whether blockade of EGFR may affect SMC
proliferation, we determined the fraction of proliferating
cells by counting BrdU-labeled nuclei. At 2 days after
balloon injury, there was a significant decrease in medial
SMC proliferation in animals that received injections of
EGFR blocking antibodies (3.2%  0.8%) compared with
those that received control antibody (8.0% 2.0%) (Fig 3).
At 7 days after balloon injury, medial SMC proliferation
was decreased in animals given anti-EGFR (5.7%  3.0%)
compared with animals that received control antibody
(10.5% 4.9%). The differences, however, did not achieve
statistical significance. At 14 days after balloon injury, the
fraction of proliferating cells decreased to about 1% in both
groups.
Two days after injury intimal SMC were not detected.
By 7 days intimal SMC were present and all cells were
proliferating (data not shown). By 14 days after injury
13.0%  2.9% of intimal cells were proliferating in the
control antibody group, compared with 17.3%  2.9% in
the anti-EGFR group. These differences were not statisti-
cally significant.
DISCUSSION
Response to arterial injury is a multifactorial process,
and many mechanisms have been described. Despite this
knowledge, no pharmacologic treatment is available to
reliably prevent deleterious narrowing of the vessel after
surgical intervention. Recent observations in cultured cells
have pointed to EGFR as a crucial mediator of various
migratory factors and mitogens.18 Other investigators19,20
have demonstrated that EGFR is expressed in the injured
vessel wall and serves as a binding site to permit delivery of
toxic drugs. However, conclusions regarding a function of
EGFR in arterial injury could not be made. In this in vivo
study we examined the effects of a EGFR blocking mAb on
intimal hyperplasia induced by balloon injury in the rat
carotid artery.
Our data clearly demonstrate that EGFR contributes to
early medial SMC proliferation and subsequent intimal
thickening. Decreased SMC proliferation on EGFR block-
ade is most significant early in the injury response, on day 2.
By day 7 the decrease in medial SMC proliferation loses
statistical significance, and by day 14 there is no longer any
difference in SMC proliferation. We did not directly inves-
tigate the effects of blocking antibody on SMC migration
from the media to the intima. However, the intima cells in
the lumen of the artery on day 7 most likely migrated from
the media. Although there was a decreased number of
intimal cells at day 7 in animals that received anti-EGFR
blocking mAb, which could suggest a decrease in SMC
migration, the differences were not statistically significant.
Intimal thickness also depends on the amount of extracel-
lular matrix present and the number of cells in the intima.
However, we did not detect any difference in cell density
per area in the intima, although there were more intimal
cells in arteries with thicker intima. This suggests that the
decrease in intimal hyperplasia in animals that received the
EGFR blocking antibody was not a result of decreased
production of extracellular matrix by the intimal cells. Last,
we observed a trend toward enhanced endothelial repair
when EGFR is blocked.
In addition to intimal hyperplasia, negative remodeling
may contribute to lumen narrowing after injury. Our data
that the external elastic laminal area was not affected by
EGFR blockade indicate that EGFR does not regulate
vessel remodeling.
How EGFR is activated after injury remains to be
elucidated. EGFR ligands are expressed as membrane-
bound precursors, and one may speculate that proteases
activated in the injured vessel wall shed these molecules and
generate soluble EGFR ligands. Moreover, EGFR activa-
tion is a pivotal process in signaling via G protein-coupled
receptor, and we recently demonstrated in vascular SMC
that thrombin-induced EGFR phosphorylation depends on
heparin-binding EGF and metalloproteinase activity.10
Thus it is likely that multiple processes initiated by injury
rely on EGFR activation.
In summary, we report a new in vivo approach to
inhibit intimal hyperplasia after balloon injury of the rat
carotid artery with administration of an EGFR blocking
mAb. Although the role of EGFR in SMC activation is
largely unknown, inhibition of medial SMC proliferation
after injury is at least partly responsible for this effect.
We thank Charles H. Fraga, University of Washington,
Seattle, for help with digital imaging.
Morphologic analysis of ballooned carotid arteries at 14 days after injury
Saline solution Control antibody Anti-EGFR
Medial area (mm2) 0.10  0.007 (n  12) (P  NS) 0.10  0.005 (n  11) (P  NS) 0.12  0.006 (n  12)
External elastic lamina area (mm2) 0.39  0.03 (n  12) (P  NS) 0.38  0.02 (n  11) (P  NS) 0.42  0.01 (n  12)
Intimal cell density (cells/0.5 mm2) 3.42  0.17 (n  5) (P  NS) 3.97  0.24 (n  6)
Note: Rats with balloon-injured carotid arteries were given intraperitoneal injections of either saline solution, control antibody, or EGFR blocking antibody.
After 14 days, the carotid arteries were perfusion fixed with 10% formalin and stained with hematoxylin-eosin. The cross-sectional images were digitally scanned
using the computer program SPOT. We determined the medial areas, areas within the external elastic lamina, and smooth muscle cell density in the intimas.
None of these parameters were statistically significantly different between control rats and animals given anti-EGFR.
EGFR, Epidermal growth factor receptor; NS, not significant.
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ANNOUNCING A NEW SECTION: VASCULAR IMAGES
The Vascular Images section presents interesting vascular images and associated short educational summaries in a
focused, case report format. One of the images will be chosen for the cover of each issue of the Journal. Submission
of color illustrations suitable for the Journal cover is encouraged. Appropriate images include radiographs, pathology,
anatomy, operative findings, and other relevant clinical pictures. The images should illustrate features of vascular
disease, including technical approaches. Illustrations and text must be confined to one printed page (no more than
350 words; perhaps less depending on the number and size of illustrations), and images for the cover should possess
both scientific and artistic merit. Descriptions of images must be included in the text, and only key references should
be provided (with a limit of two). Images must be of professional quality and should be provided electronically in
either TIFF or EPS format and uploaded (with the rest of the manuscript) via the Editorial Manager electronic
submission system at http://jvs.editorialmanager.com. Detailed artwork instructions and help with formatting,
sizing, scanning, and file naming can be found at http://www.elsevier.nl/homepage/sab/artwork. A high-
quality print or computer-generated image of each illustration must be submitted to the Journal office for accepted
submissions, even though the illustrations have been submitted previously via Editorial Manager. For more
information regarding hard copy requirements, please see “Guidelines to Complete Submission of an Accepted
Manuscript” at http://jvs.editorialmanager.com.
Contributions for the Vascular Images section are now invited.
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